A61K 38/1858
Platelet-derived growth factor [pdgf]
Official title: {Platelet-derived growth factor [PDGF]}
A61K38/1858 (Platelet-derived growth factor [pdgf]) appears on 840 US grants and 1,596 published applications in this corpus.
Search patents in A61K- Granted patents
- 840
- Published applications
- 1,596
- Assignees
- 693
- Inventors
- 2,325
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 12 | 0 |
| 1998 | 10 | 0 |
| 1999 | 9 | 0 |
| 2000 | 10 | 0 |
| 2001 | 6 | 6 |
| 2002 | 18 | 32 |
| 2003 | 11 | 49 |
| 2004 | 15 | 58 |
| 2005 | 14 | 56 |
| 2006 | 17 | 62 |
| 2007 | 22 | 61 |
| 2008 | 15 | 65 |
| 2009 | 30 | 55 |
| 2010 | 25 | 74 |
| 2011 | 23 | 69 |
| 2012 | 44 | 47 |
| 2013 | 33 | 77 |
| 2014 | 35 | 84 |
| 2015 | 41 | 108 |
| 2016 | 49 | 70 |
| 2017 | 63 | 78 |
| 2018 | 41 | 70 |
| 2019 | 48 | 80 |
| 2020 | 43 | 66 |
| 2021 | 43 | 66 |
| 2022 | 43 | 78 |
| 2023 | 32 | 53 |
| 2024 | 46 | 64 |
| 2025 | 22 | 44 |
| 2026 | 10 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Kidney-targeted drug delivery systems30 Jun 2026US 12,667,623 B2University of Mississippi Medical Center
- Tumor specific antibody conjugates and uses therefor21 Apr 2026US 12,605,469 B2OncoTAb, Inc.
- Allogeneic human plasma and platelet derived products and uses thereof17 Mar 2026US 12,576,109 B2Consano Bio, Inc.
- Bio-inspired tissue-adhesive hydrogel patch and uses thereof10 Mar 2026US 12,569,451 B2Cellartgen Inc.
- Combination grafts for tissue repair or regeneration applications10 Mar 2026US 12,569,593 B2Rejuvablast LLC
- Lifting agent with therapeutics8 Oct 2026US 2026/0306594 A1Boston Scientific Scimed, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308233 A1Regeneron Pharmaceuticals, Inc.
- Neurotrauma treatment1 Oct 2026US 2026/0295016 A1Ecole Polytechnique Federale De Lausanne (Epfl)
Most cited
By later US patents
- Three dimensional cell protector/pore architecture formation for bone and tissue constructs778US 7,713,542 B2ADA Foundation · 2010
- Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers310US 5,702,717 AMacroMed, Inc. · 1997
- Tissue volume reduction213US 6,682,520 B2Bistech, Inc. · 2004
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Tissue volume reduction191US 6,610,043 B1Bistech, Inc. · 2003